Aptar Pharma acquires Pulmotree to expand next-generation pulmonary drug delivery technology
Aptar Pharma has acquired German inhalation technology specialist Pulmotree, adding its Kolibri platform to expand next-generation pulmonary drug delivery capabilities.
The acquisition follows an existing collaboration and brings Pulmotree's Kolibri Non-Propellant Liquid Inhaler technology into Aptar Pharma's respiratory portfolio, supporting targeted delivery of inhaled medicines.
Aptar intends to accelerate development, industrialisation and commercialisation of the platform, including potential applications for complex therapeutic molecules such as biologics, although the acquisition's financial terms were not disclosed.
Field | Content |
Article Type | Deals |
Acquirer | Aptar Pharma |
Acquired Company | Pulmotree |
Deal Type | Strategic acquisition |
Transaction Status | Announced as acquired |
Announcement Date | 26 October 2026 |
Target Company Location | Germany |
Acquired Technology | Kolibri Non-Propellant Liquid Inhaler platform |
Technology Category | Pulmonary drug delivery |
Delivery Approach | Non-propellant liquid inhalation |
Therapeutic Applications | Respiratory medicines and potential complex-molecule therapies |
Potential Molecule Types | Biologics and other complex therapeutic molecules |
Prior Relationship | Existing Aptar Pharma-Pulmotree collaboration |
Strategic Focus | Development, industrialisation and commercialisation of next-generation inhalation technology |
Acquisition Consideration | Not disclosed |
Financial Terms | Not disclosed |
Regulatory Approval Status | No new medicine or device regulatory approval established by the acquisition announcement |
What Happened | Aptar Pharma acquired Pulmotree and its Kolibri inhalation technology following an established collaboration. |
Why It Matters | The acquisition broadens Aptar's respiratory drug delivery capabilities and could support development of inhaled treatments involving complex molecules. |
Strategic Rationale | Integrate specialised pulmonary delivery technology to accelerate platform development and commercialisation. |
Portfolio Impact | Adds the Kolibri Non-Propellant Liquid Inhaler platform to Aptar Pharma's technology portfolio. |
Key Takeaway | Aptar has expanded its pulmonary drug delivery portfolio through the acquisition of Pulmotree; the purchase price was not disclosed. |
What to Watch | Kolibri development milestones, industrial scale-up, pharmaceutical partnerships, regulatory progress and commercial adoption. |
Primary Source | Aptar Pharma |
Primary Source URL | https://www.aptar.com/news-events/aptar-pharma-acquires-pulmotree-expanding-growth-opportunities-in-next-generation-pulmonary-drug |
Relevant Date | 26 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments